Advertisement
U.S. markets closed

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.84+0.76 (+6.29%)
At close: 04:00PM EST
13.00 +0.16 (+1.25%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close12.08
Open12.48
Bid12.70 x 1000
Ask12.89 x 1100
Day's Range12.09 - 13.01
52 Week Range1.28 - 13.01
Volume843,186
Avg. Volume2,066,650
Market Cap630.088M
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateMar 14, 2024 - Mar 18, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NKTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Nkarta, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/20/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Nkarta to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in three upcoming investor conferences: Cowen Annual Health Care ConferenceMarch 6, 20249:10 a.m. ET – industry panel discussion Leerink Partners Global Biopharma ConferenceMarch 11, 202412:00 p.m. ET – fireside chat H.C. Wainwright Annual Cell Therapy Virtual ConferenceMarch 26, 20242:0

  • InvestorPlace

    Last Call! 7 Small-Cap Stocks Ready to Explode in Value

    The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are making waves in various industries, offering the chance to capitalize on their leads. Read more to delve into the strategies of seven such small-cap stocks poised to skyrocket in value. From the first revolutionizing financial services for the underbanked to the second groundbreaking partnership in

  • InvestorPlace

    3 Under-the-Radar Stocks Set to Soar 300% by 2026

    In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors. Amid the cacophony of market chatter are three stocks that stand out: each carves a niche in its respective industry. Each is carving a niche in their respective industries. From revolutionizing convenience store experiences to pioneering breakthrou